Implementing EMR is moving away from paper based records. This also means the need to transfer all written records from thousands of paper files and converting them digitally into EMR systems.

This process is a daunting one. It should be viewed as a long awaited opportunity to organize patient data and freeing up storage space by eliminating medical filing systems.

Some practices may decide to involve their current staff and rely on their own resources. This gives their staff a valuable experience and allows them to grasp the basics of EMR. It is easier for staff to use EMR if they are directly involve in the ‘setting-up’ of the database. By relying on available resources, the cost will involve incentives, allowances and overtime pay.

The most common approach is to outsource a firm specializing in medical record conversions. As these firms rely on conversions, the likelihood of better skilled ‘converters’ is much higher.

Outsourcing will also provide consistency in the process as well as quality control. Many companies are compliant to required standards and also to provides services that include medical records scanning, manual entry into EMR systems, chart preparation (which includes removing staplers and clips), conversion of charts to digital input, organizing charts and electronic input to EMR, EMR migration and import and secure shredding, disposal and storage of paper based records.

Many EMR vendors also provide conversion services however the cost needs to to be renegotiated. This may seem like the obvious choice but it is always good to consider available options.

The researchers collected data from 136,000 participants that were not taking antidepressant medications when they first began the study. It was noted during their first follow up between one and three years later that roughly 5,500 of those women had begun taking antidepressants. “The research team compared that group’s subsequent history of cardiovascular disease with that of participants who had not started taking antidepressants.”

Results showed that the women taking antidepressants had a small, but statistically significant increased risk of stroke and/or death compared to participants declaring that they were not taking antidepressants.

Lead author, Jordan W. Smoller, MD, ScD, of the Massachusetts General Hospital (MGH) Department of Psychiatry, explains that although it is necessary to treat depression because it is a serious illness, it is equally important for older women to discuss their treatment options with their physician before committing to one because of the various risks involved.

The DSM IV defines depression as experiencing feelings of sadness, helplessness and hopelessness. It is a state of low mood and aversion to activity. Episodes of depressed mood are a core feature in various psychological disorders.

Some symptoms of depression can include:

• Anxiety
• Sleep disturbances
• never seem to be enough
• dullness
• chronic sadness never seeming to end
• obsessions
• shakiness when feeling most down
• mood swings

Medications used to treat depression:

Tricyclic antidepressants

• Amitriptyline
• Imipramine
• Nortriptyline
• Desipramine

Side effects: Fatigue, dry mouth, blurred vision, light-headedness

Selective serotonin-reuptake inhibitors (SSRI)

• Fluoxetine
• Fluvoxamine
• Sertraline
• Paroxetine

Side effects: Nausea, gastrointestinal upset, sleep disturbances, headache, agitation

Reversible inhibitors of monoamine oxidase:

• Moclobemide

Side effects: Insomnia, headache, constipation

5-HT2 antagonists:

• Nefazodone

Side effects: Fatigue, light-headedness, nausea, headache

Serotonin-norepinephrine reuptake inhibitors:

• Venlafaxine

Side effects: Nausea, agitation, sweating

MAOIs (monoamine oxidase inhibitors):

• Phenelzine (Nardil)
• Tranylcypromine (Parnate)
• Isocarboxazid (Marplan)
• Selegiline (Emsam)

Side effects: Drowsiness, Constipation, Nausea, Diarrhea, Stomach upset, Fatigue, Dry mouth, Dizziness, Low blood pressure, Light-headedness, Decreased urination, Decreased sexual function, Sleep disturbances, Muscle twitching, Weight gain, Blurred vision, Headache, Increased appetite, Restlessness, Shakiness, Trembling, Weakness, Increased sweating

“Depression is a known risk factor for cardiovascular disease and premature death, and one of the reasons that tricyclic antidepressants are used less frequently is their potential for negative effects on heart function. Selective serotonin reuptake inhibitor (SSRI) antidepressants have fewer side effects in general and are known to have aspirin-like effects on bleeding, which could protect against clot-related cardiovascular disorders.”

Although no relationship was established between antidepressant use and heart disease, follow-up appointments nearly six years later indicated that participants using antidepressants had an increased risk of death and those treated with SSRIs had an increased risk of stroke.

Even though results seem frightening it seems to me that further investigation is needed as there are several problems with this study. The researchers have not distinguished whether the problem really lies within the link between antidepressants and cardiovascular disease or depression itself and cardiovascular disease. Prior studies will show that depression has risks that are just as high as those who use antidepressants in this study. If anything, the study may indicate that treatment with antidepressants could exacerbate those risks. After careful review of this study, it seems difficult to place blame on antidepressants, but more could be revealed with further investigation.

Additionally, the study does not specify whether these women were being treated for depression or for anxiety nor is there any indication that lifestyle factors such as stress, smoking or diet have been accounted for. Furthermore, the study is too group-specific; therefore it cannot suggest that results can be generalized to the other populations, such as men or premenopausal women unfortunately.

Despite the lack of concrete evidence, it seems logical that women with cardiovascular risks would benefit from exploring treatment options other than antidepressants, but in the end, for most, the benefits of antidepressants may far outweigh the costs.

“The randomized, double-blind, placebo-controlled clinical trial included 3,069 community-dwelling participants, ages 72 to 96 years, who received a twice-daily dose of 120-mg extract of G biloba (n = 1,545) or identical-appearing placebo (n = 1,524). The study was conducted at six academic medical centers in the United States between 2000 and 2008, with a median (midpoint) follow-up of 6.1 years. Change in cognition was assessed by various tests and measures.”

In 2000, older adults that had normal to mild cognitive impairment were chosen and observed. The researchers placed the subjects into 3 distinct groups. Some were given a placebo over the 8 year period. Others were given either Ginkgo biloba or the placebo, where their group identity was not disclosed to the participant or the experimenter. The third group was randomly assigned to either of the groups. Double-blind studies are said to achieve greater scientific rigor than other types of research. The conclusion of this double-blind study is that Ginkgo biloba is not effective in reducing the incidence of Alzheimer dementia or dementia in general. In addition, no evidence was found to support any effects on memory, language, attention, visuospatial abilities and executive functions. Furthermore, no differences were detected through age, sex, race, education or baseline cognitive status.

Basically, no evidence was found to support the widely marketed fact that Ginkgo biloba slows the rate of cognitive decline.

What is Ginkgo Biloba?

Ginkgos are very large trees, normally reaching a height of 66–115 feet, with some specimens in China being over 50 m. The tree has an angular crown and long, somewhat erratic branches, and is usually deep rooted and resistant to wind and snow damage. A combination of resistance to disease, insect-resistant wood and the ability to form aerial roots and sprouts makes ginkgos long-lived, with some specimens claimed to be more than 2,500 years old. Extreme examples of the Ginkgo’s tenacity may be seen in Hiroshima, Japan, where six trees growing between 1–2 km from the 1945 atom bomb explosion were among the few living things in the area to survive the blast. While almost all other plants and animals in the area were destroyed, the ginkgos, though charred, survived and were soon healthy again. The trees are alive to this day.

Extracts of Ginkgo leaves contain flavonoid glycosides and terpenoids and have been used pharmaceutically. Ginkgo supplements are usually taken in the range of 40–200 mg per day. Ginkgo has many alleged nootropic properties, and is mainly used as a memory and concentration enhancer, and an anti-vertigo agent. According to some studies, in a few cases, Ginkgo can significantly improve attention in healthy individuals. Allegedly, the effect is almost immediate and reaches its peak in 2.5 hours after intake.

Ginkgo has been used for…

• Alzheimer’s disease
• Improving blood flow
• Protecting against oxidative cell damage
• Blocking the effects of platelet-activating factor (platelet aggregation, blood clotting)
• Intermittent claudication
• Easing the symptoms of tinnitus
• Improving cognition and fatigue in those with multiple sclerosis
• Arresting the development of vitiligo

Ginkgo may have undesirable effects, especially for individuals with blood circulation disorders and those taking anticoagulants such as ibuprofen, aspirin, or warfarin. Ginkgo should also not be used by people who are taking certain types of antidepressants (monoamine oxidase inhibitors and selective serotonin reuptake inhibitors) or by pregnant women, without first consulting a doctor.

Side effects can include…

• possible increased risk of bleeding
• gastrointestinal discomfort
• nausea
• vomiting
• diarrhea
• headaches
• dizziness
• heart palpitations
• restlessness

Other precautions…

Ginkgo biloba leaves contain long-chain alkylphenols together with the extremely potent allergens, the urushiols (similar to poison ivy). Individuals with a history of strong allergic reactions to poison ivy, mangoes, and other urushiol-producing plants are more likely to experience an adverse reaction when consuming Ginkgo-containing pills, combinations, or extracts.

The nut-like gametophytes inside the seeds are particularly esteemed in Asia, and are a traditional Chinese food. When eaten by children, in large quantities (over 5 seeds a day), or over a long period, the raw gametophyte (meat) of the seed can cause poisoning by MPN (4-methoxypyridoxine).

Bottom line…

It is very important to remember that herbal supplements are not regulated by the FDA in the US and Canada’s regulation of such health products is quite often confusing and inconsistent. Therefore, personal responsibility is essential when relying on this type of treatment.

The American Academy of Neurology Guidelines ranks the severity of a concussion into 3 grades:

Grade I – Confusion, symptoms last

Grade II – Symptoms last 15 minutes, no loss of consciousness

Grade III – Loss of consciousness

Concussion Symptoms:

• Headache
• Dizziness
• Vomiting
• Nausea
• Lack of motor coordination
• Difficulty balancing
• Light sensitivity
• Seeing bright lights
• Blurred vision
• Double vision
• Tinnitus
• Convulsions
• Confusion
• Disorientation
• Difficulty focusing attention
• Loss of consciousness
• Post-traumatic amnesia
• Confusion
• Slurred or incoherent speech
• Changes in sleeping patterns
• Difficulty with reasoning, concentrating, and performing everyday activities
• Crankiness
• Loss of interest in favorite activities or items
• Tearfulness
• Displays of emotion that are inappropriate to the situation

**Common symptoms in children include restlessness, lethargy, and irritability.

Typically symptoms will go away without treatment. Roughly 1% of treated concussions require surgery for a brain injury. Most often plenty of rest is prescribed with a gradual return to normal activities at a pace that does not cause symptoms to worsen.

Medications may be prescribed to treat symptoms associated with the concussion, such as sleep problems and depression. Analgesics such as ibuprofen can be taken for headaches that frequently occur after a concussion, but acetaminophen is preferred to minimize the risk for complications, such as intracranial hemorrhage. Individuals are advised not to drink alcohol or take drugs that have not been approved by a doctor as they may interfere with the healing process.

Observation to monitor for worsening condition is an important part of treatment. Unconsciousness or altered mental status, convulsions, severe, persistent headache, extremity weakness, vomiting, or new bleeding or deafness in either or both ears suggests that another visit to the doctor is needed. No conclusive evidence suggests that it is necessary to wake a patient up every few hours or not.

Symptoms usually go away entirely within three weeks, though they may persist, or complications may occur. Although the mortality rate is almost zero, repeated concussions can cause cumulative brain damage such as dementia pugilistica or severe complications such as second-impact syndrome.

Certain factors may lengthen recovery time, such as longer periods of amnesia or loss of consciousness, substance abuse, clinical depression, poor health or additional injuries sustained and life stress. For unknown reasons, having had one concussion significantly increases a person’s risk of having another. Having previously sustained a concussion has been found to be a strong factor increasing the likelihood of a concussion in the future. The prognosis is likely to differ between adults and children; however little research has been done on concussion in the pediatric population. Concern exists that severe concussions could interfere with brain development in children.

A 2009 study published in Brain found that individuals with a history of concussions might demonstrate a decline in both physical and mental performance for longer than 30 years. Compared to their peers with no history of brain trauma, victims of concussion exhibited the following effects:

• A decrease in episodic memory (times, places, associated emotions, and other contextual knowledge)
• A decrease in response inhibition
• Delayed P3a/P3b waves recorded via EEG
• An increase in the cortical silence period
• Reduced muscle speed otherwise known as bradykinesia (slow movement)

In recent news, Canadian researchers suggest that the term concussion is scraped from medical terminology as doctors and parents quite often underestimate the severity of these types of injuries.

“Carol DeMatteo, an occupational therapist and associate clinical professor in the School of Rehabilitation Science at McMaster University in Hamilton, Ont., says children diagnosed with concussions are treated differently from kids with other mild brain injuries.” These children are often sent home from the hospital and returned to school much sooner than those treated for mild brain injuries.

The term mild brain injury takes on a more negative connotation that concussion, which tends to suggests that the prognosis is obviously good. Concussion should not be taken as lightly as evidence suggests people who have experience multiple concussions risk neurological damage or even Alzheimer’s disease and other dementias.

Natasha Richardson’s tragic death is a perfect example of what might happen when brain injuries are not taken seriously enough. On 16 March 2009, Richardson sustained a head injury when she fell while taking a skiing lesson at the Mont Tremblant Resort in Quebec. The injury was followed by a lucid interval, when she appeared to be fine as she was able to talk and act normally. Paramedics were told they were not needed. She returned to her hotel room and about three hours later was taken to a local hospital in Sainte-Agathe-des-Monts after complaining of a headache. About 7 hours following her fall, she was transferred by ambulance to Hôpital du Sacré-Cœur, in Montreal, in critical condition. The following day she was flown to Lenox Hill Hospital in New York City, where she died on 18 March. An autopsy conducted by the New York City Medical Examiners Office on 19 March revealed the cause of death was an “epidural hematoma due to blunt impact to the head”, and her death was ruled an accident. There is a lot of controversy surrounding her death as many believe it could have been prevented with proper medical care.

If the term “mild traumatic brain injury” replaced “concussion”, it would help people understand that this type of injury is serious and that it is an injury to the brain, not just the head. It could also save lives and prevent more serious complications later in life.

PTSD is common in soldiers returning from combat duty, victims of sexual or physical assault and survivors of imprisonment or hostage situations. It is also common among individual that have experienced acts of terrorism, accidents or natural disasters and those diagnosed with a life-threatening illness. Conventional approaches to treat PTSD include antidepressant medication and psychotherapy; however recovery rates are far from acceptable.

“Exposure therapy has been recognized as a highly promising method for treating patients with PTSD. Rather than relying on patients’ visualization skills to ‘relive’ the traumatic experience, technological strategies such as virtual reality (VR) provide a controlled environment in which patients can experience a situation or scenario while learning to cope with their emotional responses.”

When natural disasters occur relief efforts typically focus on immediate needs, such food, clothing, shelter, first aid, emotional support and family reunification. Treatment of ongoing mental health should play a vital role in the response. The implementation of this type of tool could have major benefits for mass casualty survivors.

In Haiti, for instance, individuals are experiencing major losses that will affect them for years to come. The loss of loved ones, displacement, medical injuries and material loss are all psychologically devastating. In addition, the victims of this tragedy are likely to be disturbed by memories of the trauma and experience flashbacks of mass graves and friends, neighbours and even family members burned or trapped under collapsed buildings. Furthermore, the destroyed buildings and homes, and the absence of family members will continue to serve as traumatic reminders.

“‘Empty situations’ posed by the sense of an absence of personal location, deprives the victim of a safe ‘holding environment’ so necessary for the recovery process. These secondary adversities caused by displacement function as a barrier to the effort required in ‘processing’ the trauma of personal loss.” Rebuilding the lost structure in their lives is necessary for recovery, however efforts cannot end there. Extended treatment is essential to full or near full recovery, therefore, funding should be applied to ongoing mental health treatment. Virtual reality treatment in safe clinical settings could be part of that effort.

Virtual reality treatment is not a quick fix. It consists of many sessions of gradual exposure and it is most often combined with cognitive behavioral therapy and anxiety management in order to cope with the recreation of the traumatic events. It is important to note that the virtual recreation consists only of certain aspects of the event and not the exact recreation of the event itself.

Evidently, time, money and effort of this type of approach far exceeds the efforts of distributing supplies, however success rates are far more important than quick and easy methods. Moreover, this type of therapy should really be considered for relief personnel as their mental health is also at risk from their experiences. Recovering from the effects of a natural disaster is a lengthy process and the treatment for its effects on mental health is an even lengthier one.

“Chitosan (pronounced /ˈkaɪtɵsæn/) is a linear polysaccharide composed of randomly distributed β-(1-4)-linked D-glucosamine (deacetylated unit) and N-acetyl-D-glucosamine (acetylated unit).” It is produced commercially by deacetylation of chitin, a derivative of glucose. Chitin can be found in crabs, lobsters, shrimps, insects, squid, octopuses and cell walls of fungi to name a few.

Firstly, the researchers converted chitin to chitosan. They then isolated and compressed a segment of a guinea pig’s spinal cord. Following this, they applied chitosan and a fluorescent dye into the cells through damaged membranes. All of the neurons in the spinal cord tissue remained unstained by the dye under the microscope. While measuring the guinea pig’s brain response, it was noted that signals could not reach the brain because of the damaged spinal cord. “However, 30•min after injecting chitosan into the rodents, the signals miraculously returned to the animals’ brains.” Hence, the nerve cells had been successfully repaired.

Borgens and his team also discovered that the levels of LDH leakage from the spinal cord tissue treated with chitosan were lower than those in undamaged spinal cords. “Lactate dehydrogenase catalyzes the interconversion of pyruvate and lactate with concomitant interconversion of NADH and NAD+. It converts pyruvate, the final product of glycolysis to lactate when oxygen is absent or in short supply, and it performs the reverse reaction during the cori cycle in the liver.” Understanding the function of LDH is quite complex, however, in layman’s terms, high levels of LDH are an indication of tissue breakdown or necrosis.

In addition, the researchers uncovered that the sugar repaired any damaged portions of the cell membrane, not only the compressed portion. During their studies, they also found that chitosan could likely be used to repair mitochondrial membranes. “Mitochondria have been implicated in several human diseases, including mitochondrial disorders and cardiac dysfunction, and may play a role in the aging process.” Could further research lead to developing treatments for certain genetic disorder and neurodegenerative diseases?

Article source: http://feedproxy.google.com/~r/mentalhealthblog/hWNm/~3/CIlDH60oWMQ/chitosan-could-heal-spinal-cord.html

“Functional Magnetic Resonance Imaging (fMRI) is a type of specialized MRI scan. It measures the hemodynamic response (change in blood flow) related to neural activity in the brain or spinal cord of humans or other animals. It is one of the most recently developed forms of neuroimaging. Since the early 1990s, fMRI has come to dominate the brain mapping field due to its relatively low invasiveness, absence of radiation exposure, and relatively wide availability.”

“So-called “neuromarketing” takes the tools of modern brain science, like the functional MRI, and applies them to the somewhat abstract likes and dislikes of customer decision-making. Though this raises the specter of marketers being able to read people’s minds (more than they already do), neuromarketing may prove to be an affordable way for marketers to gather information that was previously unobtainable, or that consumers themselves may not even be fully aware of, says Dan Ariely, the James B. Duke professor of psychology and behavioral economics at Duke.”

In essence, the results from the study of brain scans that boost sales for materialistic items like food and cars is viewed as more valuable than the understanding of mental illness. Evidently, many people view this as a misuse or abuse of valuable medical resources in an attempt at controlling society.

There is no need to describe the obvious ethical issues involved in such techniques that allows marketers to peek into the brains of their consumers, but considerations must be given to consumers’ awareness, consent, and understanding of what could be an invasion of privacy. Moreover, how could toy companies employ such a method?

Despite these concerns, this type of marketing technique could actually do some good by reducing the number of advertisements that use shock tactics and sexual imagery as main selling points for their products. In addition, companies might actually improve their products to meet consumer expectancy.

Obviously the main function of this technique is not to increase scientific knowledge, but a by-product of such marketing tools could lead to a better understanding of how the human brain creates, stores, recalls and relates information. Furthermore, side-effects of such studies could also mean healthier advertising, for instance, reducing negative influences that lead to over-consumption.

If this is where advertising is going, we can only hope that companies will employ professionals to interpret the brain scans as images must be carefully interpreted by individuals with extensive training since misinterpretation could have serious consequences, even for companies promoting their products.

“Neuromarketing may never be cheap enough to replace focus groups and other methods used to assess existing products and advertising, but it could have real promise in gauging the conscious and unconscious reactions of consumers in the design phase of such varied products as “food, entertainment, buildings and political candidates,” Ariely says.”

Nonetheless, there could never be enough benefits from this type of marketing to hold more value than the fMRI’s initial intent, in my opinion.

How exactly can our breaths achieve such feats? “The new system identifies changes in air pressure inside the nostrils and translates these into electrical signals.” Testing was completed with volunteers and quadriplegics and results proved to be very promising. The subjects were able to manoeuvre a wheelchair or play a computer game with as much ease and precision as with a mouse or joystick.

Sniffing is a precise motor skill that is controlled, in part, by the soft palate […] the soft palate is controlled by several nerves that connect to it directly through the braincase. This close link led Sobel and his scientific team to theorize that the ability to sniff — that is, to control soft palate movement — might be preserved even in the most acute cases of paralysis. Functional magnetic resonance imaging (fMRI) lent support to the idea, showing that a number of brain areas contribute to soft palate control. This imaging revealed a significant overlap between soft palate control and the language areas of the brain, hinting to the scientists that the use of sniffing to communicate might be learned intuitively.

From this theory, a device that measures changes in air pressure was created with a sensor that fits into the opening of the nostrils. Furthermore, an alternate version that diverts air into the nostrils was produced for patients on respirators. Interestingly, roughly 75% of those on respirators could control and operate the device.

Still, the most striking is that individuals with locked-in syndrome, a state in which their cognitive functions are intact but their bodies are completely paralyzed so that they are “locked” inside their bodies, were able to communicate effectively with their loved ones on account of this new invention. Finally, these patients were able to share their thoughts and feelings with their families for the first time in a very long time.

“One patient who had been locked in for seven months following a stroke learned to use the device over a period of several days, writing her first message to her family. Another, who had been locked in since a traffic accident 18 years earlier wrote that the new device was much easier to use than one based on blinking. Another ten patients, all quadriplegics, succeeded in operating a computer and writing messages through sniffing.”

Moreover, wheelchair navigation can be done effortlessly with this technology. A certain number of inhales or exhales instruct the chair to navigate in certain directions. Two successive sniffs will make the wheelchair advance forward and two exhales will reverse the chair. One inhale followed by an exhale will steer to the left, while an exhale followed by an inhale steers to the right.

Consequently, the technology has received such acclaim that four of the research subjects are still using the device to communicate. Researchers’ claim that this system is fairly inexpensive to manufacture, not to mention easy for people to learn and operate in comparison to other types of similar technology already in use. Yeda Research and Development Company are currently looking to develop and distribute the technology to the general public, therefore it may not be long until this technology is put to good use.

Scientists implanted “electrodes in the brain’s hippocampus, which plays a role in long-term memory. The electrical conductor acts as a pacemaker-like device in the head just beneath the skin. It is connected to a battery pack in the chest.”

Consequently, the mini-mental state exam, a cognitive test, revealed that half of the participants experienced a slow-down in the degenerative effects Alzheimer’s disease has on the brain, while the other half continued to decline in a manner typical of the disease’s progression.

While this new research has produced some promising results, deep brain stimulation is not a novel idea since it has been around for decades. For instance, Dr. Andres Lozano, a neurosurgeon at Toronto’s University Health Network, experimented with its effects on Parkinson’s disease without success, unfortunately.

Although not all subjects experienced positive outcomes with this surgery, 64 year old, former city counselor from Brampton, Ontario, Robert Linton, recalled vivid memories of a day he spent fishing.

“I’m with my son,” Linton recalled to reporters at Toronto Western Hospital. “I could see that muskie coming right at me as I was sitting in the chair, in Technicolor”. “That’s the power of touching a spot in your brain. I’m sold on it.”

Currently, Lozano and his research team are recruiting roughly 50 people willing to install the stimulator. The plan is to activate half of the stimulators immediately and the other half only six months later all the while participants’ knowledge of its activation will remain unknown in order to truly test the benefits of the device.

Although, the true value of this device is not yet known, the actual retail cost if this treatment became available, would be between $15,000 and $20,000 per patient with a battery life of up to five years.

At the moment, I’m unsure whether I approve of this type of treatment. For one, results are insufficient therefore there is no real proof that the surgery will benefit enough people. Secondly, I am reminded of electroconvulsive therapy and I cannot get the image of Nurse Ratched delivering shock therapy out of my head…

Ketamine is a fast-acting liquid anesthetic used mainly by veterinarians; it’s also used in human medicine, even in children, because it doesn’t depress breathing.

It’s also an illegal club drug, known as “special K” or “vitamin K.”

The street version is usually sold in a powder form that can be snorted or mixed into drinks, or dissolved into a liquid and injected.

It acts like LSD, causing vivid hallucinations in users and a sensation of floating outside their bodies.

Researchers at Yale University have discovered that a single dose of ketamine helps the brain to form new synaptic connections between neurons and can begin to relieve depressive symptoms in a little as 40 minutes.

In contrast, Prozac and other types of antidepressants can take anywhere from two weeks to a full month before they start to demonstrate any real results, in which benefits can only be seen in about a third of patients. This new antidepressant is now being tested in Canada with promising results.

Dr. James Kennedy, director of the neuroscience research department at the Centre for Addiction and Mental Health in Toronto states that ketamine might alleviate what has been known as a “major clinical problem”. The 2 – 4 weeks that patients await relief is a critical time where devastating outcomes, such as suicide, can occur because they begin to feel more energetic but depressive symptoms remain. Not only is there hope for those with difficult to treat depression, ketamine could actually save lives.

Earlier studies involving patients with “treatment-resistant” depression have found that those given a single dose of ketamine experience rapid and significant improvement in symptoms.

In a small study published earlier this month on patients with bipolar depression, 71 per cent of participants responded to ketamine versus six per cent who responded to placebo.

In addition to being fast-acting, studies show that relief can last for 7 – 10 days, according to professor of psychiatry and neurobiology at Yale, Ronald Duman, who calls ketamine a “magic drug”.

Duman also believes that this so-called magic drug may be able to reverse the effects of stress on the brain by repairing damaged connections between neurons caused by chronic stress.

Although ketamine may not be the ideal long-term solution for treating depression, it could certainly lead to the development of similar compounds that may produce the same effect, but can be more easily administered with less potential for abuse.

“Imagine someone who is in the ER (emergency department) and is highly suicidal. It would be a way to decrease the suicidal risk” says Dr. Pierre Blier, director of mood disorders research at the Institute of Mental Health Research and Canada Research Chair in Psychopharmacology at the Royal Ottawa Mental Health Centre, who has started using ketamine on some of his patients.